Edwards Lifesciences Corp EW

Business model and Optionality hold this up; Valuation is the soft spot.

The price needs 15.0% growth a year for ten years. The AI thinks 10.0% is achievable, at a 25.0% margin.

At a 25% cash flow margin, EW requires 15% growth to justify its price, exceeding the assessed 10% achievable rate and creating a -5% gap signaling overvaluation.

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Write why this business works, set your own fair value, and let the briefing speak only when a rule you wrote is crossed.